Humanin
HN / Mitochondrial-Derived Peptide
A 24-amino-acid mitochondrial-derived peptide (MDP) encoded by the 16S rRNA gene. The first identified MDP, Humanin exhibits potent cytoprotective effects against apoptosis triggered by amyloid-beta, oxidative stress, and serum starvation. Endogenous levels decline with age, making exogenous supplementation a target for longevity and neuroprotection research.
Half-life
~2–4 hours
Typical Dose
1–5 mg/day
3/5Route
subcutaneous
Category
longevity
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How Humanin is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 1–5 mg/day. Half-life: ~2–4 hours. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Humanin is a mitochondrial-derived peptide that inhibits apoptosis triggered by amyloid-beta, oxidative stress, and serum starvation. Preclinical studies show cytoprotection, anti-amyloid-beta activity, vascular endothelium protection, and improved insulin sensitivity. Endogenous levels decline ~40% between ages 40-60.
- Hashimoto et al., 2001 — Discovery of Humanin, PNAS
- Muzumdar et al., 2009 — Humanin improves insulin sensitivity
- Preclinical neuroprotection research against amyloid-beta
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for Humanin and 90+ other compounds with Pro.
Upgrade to ProSafety & Contraindications
- No completed human clinical trials for therapeutic use
- Safety profile not fully established
- Pregnancy or breastfeeding
Humanin: common questions
What is Humanin?
A 24-amino-acid mitochondrial-derived peptide (MDP) encoded by the 16S rRNA gene. The first identified MDP, Humanin exhibits potent cytoprotective effects against apoptosis triggered by amyloid-beta, oxidative stress, and serum starvation. Endogenous levels decline with age, making exogenous supplementation a target for longevity and neuroprotection research.
How is Humanin dosed?
Humanin is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 1–5 mg/day. Experimental (early or animal data): 1–5 mg/day subcutaneous; Daily; 4–8 week cycles with 4-week breaks. These ranges describe what has been studied or used; they are not a prescription.
Is Humanin FDA-approved?
No. Humanin is not approved by the FDA for any use in people.
What is the half-life of Humanin?
DoseCraft's library lists a half-life of ~2–4 hours. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use Humanin?
Listed contraindications: No completed human clinical trials for therapeutic use; Safety profile not fully established; Pregnancy or breastfeeding.
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.